Sears 2013 — Chelation: harnessing and enhancing heavy metal detoxification (review)

Sears, at the Children’s Hospital of Eastern Ontario Research Institute (Ottawa), reviews chelation as both a natural toxicokinetic process and a pharmaceutical intervention for elevated body burden of toxic metals. The manuscript stems from a Canadian Institutes of Health Research-funded scoping review on arsenic, cadmium, lead, and mercury and is the narrative companion to the systematic review of metals-in-sweat data the same group published in 2012 (Sears, Kerr, Bray, Journal of Environmental and Public Health, 184745). The paper is structured around (i) chelation chemistry and the biological roles of endogenous chelators (glutathione, metallothionein), (ii) dietary and supplemental compounds proposed as detoxification adjuncts, (iii) the five pharmaceutical chelators in widest clinical use, (iv) controversies (EDTA-related deaths, the Stangle DMSA rat study and its consequences for paediatric chelation), and (v) clinical applications spanning lead poisoning, mercury vapour exposure, cardiovascular disease, autism-spectrum trials, and renal protection. There are no primary occurrence measurements and no original analytical data; the value to the wiki is conceptual and vocabulary-organising, not quantitative-evidence.

Why this matters

• It is the standard peer-reviewed narrative survey of pharmaceutical chelation as practised in North America in the early 2010s, and is the canonical secondary reference cited in subsequent reviews on metal detoxification. Subsequent literature (Flora & Pachauri 2010, Bjørklund et al., Sears 2018) builds on its taxonomy.
• It catalogues the five chelating drugs the US National Library of Medicine recognises as most commonly used against heavy-metal intoxication — dimercaprol (BAL), DMSA (succimer), DMPS, CaNa2EDTA, and D-penicillamine — and reports for each the activation/metabolism pathway, coordination donor atoms, and the set of elements the drug chelates. This table is the source’s main reference contribution.
• It frames glutathione (a tripeptide, gamma-Glu-Cys-Gly) and metallothionein (a cysteine-rich, 6-7 kDa metal-binding protein) as the two endogenous peptide chelators central to natural detoxification. This is the directly peptide-relevant content for the Black Market Peptide Metal Survey folder context: the paper anchors the biochemistry of endogenous peptide chelation that downstream pages on metallothionein-based and glutathione-based detoxification can reference.
• It is one of the few peer-reviewed sources that pulls clinical trial evidence (TACT, Cincinnati cohort, Adams autism trial, Lin diabetic-nephropathy trial) into a single narrative, allowing the wiki’s metal pages to characterise the state of chelation evidence by element without rederiving each trial.

Endogenous peptide chelation

The review identifies two endogenous peptide-class chelators central to natural detoxification kinetics.

• Glutathione (GSH) — tripeptide gamma-Glu-Cys-Gly. The review describes glutathione as “another potent chelator involved in cellular response, transport, and excretion of metal cations” and as a biomarker for toxic metal overload. The paper notes that glutathione is poorly absorbed orally because it is digested, and that novel delivery routes (liposomal, prodrug, intravenous, topical, nebulised) are emerging. Reduced glutathione protects cells from reactive oxygen species generated by heavy-metal exposure.
• Metallothionein (MT) — cysteine-rich metal-binding protein. The review describes MT as central to the natural response to cadmium and other toxic elements; metallothionein content of foods is noted as a factor modulating bioavailability and metabolism of cadmium (per Klaassen, Liu, Diwan 2009; the review’s reference 28). The review does not enumerate the MT isoforms in detail but flags MT as the foundational peptide chelator for cadmium handling in particular.

The peptide and amino-acid building blocks for these endogenous chelators (cysteine, methionine, selenomethionine, taurine) appear repeatedly in the review’s discussion of supportive supplementation, with three positioned as directly therapeutic: taurine (refs 49-51), methionine (ref 52), and N-acetylcysteine (NAC, the orally bioavailable cysteine precursor, refs 54-56). Alpha-lipoic acid (a fat- and water-soluble metal-chelating antioxidant that regenerates other antioxidants and crosses the blood-brain barrier) is described as a metal chelator in its own right but is flagged as carrying redistribution risk if used carelessly.

Pharmaceutical chelators (source Table 1, p. 4)

The review tabulates the five chelating drugs the US National Library of Medicine recognises as most commonly used for heavy-metal intoxication. The columns are chemical name (with common names and abbreviations), molecular structure (omitted here — graphic in source), activation/metabolism, coordination donor groups, and elements chelated.

(Trade names retained because Table 1 catalogues drug-label vocabulary, not contamination measurements on consumer products; the table is method/agent nomenclature, parallel to instrument-vendor names in a Methods section, and is preserved as the source’s controlled vocabulary. See Verification notes.)

Pharmacokinetic parameters reported

• DMSA oral absorption ≈ 20%, with the majority of absorbed drug protein-bound (≈95%, mainly to albumin). 10-25% of an oral dose is excreted in urine (largely as DMSA-cysteine disulfide conjugates) within 24 hours; the remainder is eliminated in faeces. Plasma half-life ≈ 3 hours, longer in children and patients with high toxic-metal burden.
• DMPS oral absorption ≈ 39% (higher than DMSA). Solutions are relatively stable, permitting more frequent IV administration than DMSA. DMPS is rapidly converted to a disulphide form and excreted largely in urine as acyclic and cyclic disulphide chelates; overall half-life ≈ 20 hours after IV administration. A significant proportion is also excreted in bile.
• CaNa2EDTA is not metabolised. EDTA chelates are rapidly excreted, principally in the urine. CaNa2EDTA is distributed mainly in the extracellular fluid; redistribution of lead from tissues to brain has been reported as a perceived drawback in some accounts.
• BAL is dithiol prepared in oil base, given by intramuscular injection (painful), with a narrow therapeutic window. Risk of allergic reaction from peanut-oil preparation.
• Penicillamine is used principally for Wilson’s disease (copper). It mobilises As, Cd, Pb, and Hg but is generally not a drug of choice and is inferior to DMSA and DMPS in removing methylmercury from animals (with no effect on brain levels).

Canadian clinical toxicologist preferences (source p. 5, citing the questionnaire results)

Responding clinical toxicologists at Canadian Poison Control Centres indicated their preferences for chelation therapy as follows. The review does not report the response rate, the number of respondents, or the regional distribution of respondents; the result is reported as a narrative consensus, not a quantitative survey.

Natural-chelation dietary and supplemental agents

The review enumerates dietary materials and supplements proposed as detoxification adjuncts. These claims are review-level summaries of underlying primary studies (mostly animal or small-n human work) and are reported here as the source’s organised vocabulary, not as endorsed efficacy claims.

• Dietary fibre — bran (cereals, oat) and fruit fibre have been studied as alternatives or adjuncts to chelation therapy with the goal of interrupting enterohepatic recirculation (refs 34-36) and modulating intestinal flora (ref 37), with reductions in mercury in brain and blood observed in animal work. Caution flagged for soluble fibre: flax seed resulted in increased intestinal absorption of cadmium (ref 38).
• Modified citrus pectin + alginate — five case reports of reduced lead and mercury (Eliaz, Weil, Wilk 2007, ref 39).
• Algal polysaccharides (alginate) and chlorella discussed as candidate adsorbents.
• Poly(gamma-glutamic acid) — edible biodegradable biopolymer produced extracellularly during Bacillus fermentation; alpha-carboxyl groups conjugate metal cations (ref 41).
• Alliums (garlic) — sulfur-containing peptides; ref 42 (Abdalla et al., garlic prevented methylmercury cytotoxicity in peripheral blood leukocytes); ref 44 (Suru: onion and garlic extracts lessen cadmium nephrotoxicity in rats); ref 45 (Senapati: garlic extract decreased blood lead levels in rats).
• Brassicas (broccoli) — glucosinolate-derived sulfur compounds (ref 43).
• Cilantro (Coriandrum sativum) — culinary herb with conflicting evidence. Aga et al. 2001 (ref 47): preventive effect on lead deposition and ALAD enzyme inhibition in ICR mice. Deldar 2008 (ref 48): cilantro extract effective as placebo only in 3-7-year-old children exposed to lead — improvements in both treatment and placebo groups attributed to improved diet during the intervention.

Clinical-trial evidence the review cites

The review compiles clinical-trial outcomes by application area. The Numbers below are quoted from the source.

• Lead poisoning in adults (DMSA case series, Bradberry et al., ref 102): DMSA chelation therapy increased lead excretion on average by a factor of 12 and rapidly reversed lead-related symptoms (largely neurological and gastrointestinal) in a case series of 17 lead-poisoned adults.
• Mercury vapour poisoning (DMPS case report, ref 103): A jeweller with extensive neurological symptoms of mercury vapour poisoning, reversed with DMPS treatment.
• Mercury exposure community trial (DMPS, Philippines, ref 104): Two weeks of oral DMPS in a community highly exposed to mercury from artisanal gold mining produced “multiple significant neurological improvements” in most participants. The review characterises this trial as high-quality with careful descriptions of intervention, inclusion criteria, dropouts, and results, and as remarkable for the level of acute testing conducted in a remote location and the near-perfect compliance achieved with midwife-distributed medication.
• Lead chelation in children (Rogan et al. 2001 NEJM Cincinnati cohort, ref 89): N = 780 children. Blood lead temporarily lowered in treated group; at 36-month follow-up, blood lead levels in treated children had rebounded and there were no significant differences in blood lead or neurocognitive outcomes between treatment and control. Aggressive protocol of 26 days of therapy for one, two, or three rounds may have depleted essential minerals in a vulnerable population (poor, inner-city, Black/Hispanic children); vitamin and mineral supplementation may have been inadequate.
• Autism + DMSA (Adams et al., ref 96, Journal of Toxicology): Severity of autism associated with toxic metal body burden and red-blood-cell glutathione. The follow-on Adams DMSA trial (Adams et al., ref 105, BMC Clinical Pharmacology) demonstrated significant positive association between severity of autism and body burden of toxic metals, and efficacy of reduction of this body burden in improving symptoms.
• Lead body burden and renal function (Lin et al., refs 106, 107): Patients with chronic renal insufficiency without diabetes (n = 64): three months of CaNa2EDTA weekly infusions resulted in slowing or reversing renal degeneration in the chelation group; 24 further months of treatment in n = 32 patients with elevated body lead burdens improved glomerular filtration rate among treated group and decreased it in controls; cost reported as approximately $3,750perpatientversus$61,000 for haemodialysis over a similar time frame. Smaller trial in type II diabetes patients (ref 107): body lead burden was a strong predictor of renal function decline; chelation halved rate of decline during three months of treatment.
• TACT (Trial to Assess Chelation Therapy; Lamas et al., ref 110, US NIH-sponsored): N = 1,708 non-smokers aged 50+ with prior acute myocardial infarction. Forty 3-hour infusions of multicomponent Na2EDTA solution plus an oral high-dose multivitamin/mineral supplement on non-chelation days. Primary composite endpoint (all-cause mortality, MI, stroke, coronary revascularisation, hospitalisation for angina): 18% reduction in the EDTA group versus placebo (P = 0.03) three years after treatment. Diabetic subgroup and those with anterior MI: combined endpoint reduced by 39% (P = 0.002). No difference between groups in serious adverse events; hypocalcaemia and transient renal function impairment (the two complications previously reported with primitive protocols) did not occur. The TACT proceeded despite detailed criticisms (ref 112); urinary excretion of toxic elements was not assessed during the trial.

Reported adverse events and safety considerations

• Three deaths associated with Na2EDTA (CDC, ref 84) attributed to hypocalcaemia resulting in cardiac arrest. The review notes these were drug errors and should not reflect on the safety of CaNa2EDTA, which is the form generally indicated for chelation of toxic metals.
• Transient increases in hepatic transaminase activity reported with CaNa2EDTA, DMSA, and DMPS, resolving on discontinuation.
• Skin lesions associated with CaNa2EDTA possibly related to zinc deficiency.
• Mucocutaneous eruptions and toxic epidermal necrolysis (rare) reported with DMSA, resolving on discontinuation.
• Allergic reactions reported with DMSA and DMPS, less commonly with CaNa2EDTA; allergy testing may precede chelation therapy in selected cases.
• Lead redistribution to brain with CaNa2EDTA — mixed reports; some accounts hold that EDTA does not cross the blood-brain barrier, while other reports describe increased symptoms of lead poisoning or mercurialism during EDTA therapy (ref 87).
• Stangle et al. rat study (ref 92): DMSA in lead-exposed rats from early postpartum to late adolescence improved learning, attention, arousal regulation, and reduced blood and brain lead levels. The same study detected adverse cognitive effects of DMSA in unexposed untreated rats. The protocol used was 50 mg/kg/day DMSA for 21 days — much higher than the US FDA-approved maximum label dose of 30 mg/kg/day (ref 93) and given for longer than the typical paediatric course of less than a week (ref 96). The detection of cognitive effects in unexposed rats prompted cancellation of a planned NIH clinical trial of DMSA in autism (ref 91). Sears notes that the Stangle protocol “violated important current clinical practices” through high dose, extended duration, absence of indication of need, and failure to assess essential minerals.

Methods (brief)

The paper is a narrative review of the chelation literature with no original experimental work. Inputs as declared by the author: online literature searches across research publication databases (search strategy not disclosed in this manuscript but described as “previously” in Sears, Kerr, Bray 2012), governmental sources (Environment Canada, US EPA), nongovernmental sources (WHO), expert opinion solicited via email, a conference call, and a two-day conference in Toronto (February 2011), and a survey of clinical toxicologists at Canadian Poison Control Centres regarding screening, experiences, and preferred chelators per toxic element. Ethics approval obtained from the Children’s Hospital of Eastern Ontario Research Institute. Funding: Canadian Institutes of Health Research. The author declared no conflicts of interest. Editors: C. Montoliu, J. Pungercar, J.-M. Sabatier, F. Thévenod, A. Yasutake.

The review does not declare PRISMA-style inclusion/exclusion criteria, risk-of-bias assessment, or a quantitative synthesis. It is a narrative review with 122 references.

Implications

• Certification: The review reports no occurrence data and contributes nothing directly to HMTc threshold-setting work. Its indirect value is in establishing that chelation therapy is the established standard of care for high body burdens of Pb, Cd, As, and Hg, which is the clinical backdrop against which dietary-exposure reduction programmes (the HMTc focus) are framed. No HMTc rationale tag is appropriate; the source is excluded from pool admission for any percentile-selection arithmetic.
• App: No routing to ingredient or product pages. The source contributes background reading for [[metals/lead]], [[metals/cadmium]], [[metals/arsenic-inorganic]], [[metals/arsenic-total]], [[metals/mercury-methyl]], [[metals/mercury-total]], and [[metals/tin]] on the topic of clinical detoxification options and endogenous chelation biochemistry, not on contamination occurrence.
• Courses: Useful as a primary teaching reference for an educator-audience module on the clinical pharmacology of chelation, the pharmacokinetic differences among the five major chelators, and the trial evidence underpinning current paediatric and adult chelation practice. Quote-sized claims should be traced to the named primary references (Stangle, Rogan, Lamas, Lin, Adams) rather than to this review.
• Microbiome: Marginal. The review mentions bran-fibre modulation of intestinal flora (ref 37) as a candidate route for mercury reduction in brain and blood, but does not engage the gut-microbiome-metal axis in depth. The Bacillus poly(gamma-glutamic acid) fermentation example is microbiome-adjacent but not direct gut-microbiome material. WikiBiome federation is unlikely to draw on this source.
• Mitigation evidence: Most relevant to [[mitigation/remediation-evidence]] as a clinical-detoxification reference rather than environmental remediation. The endogenous-chelation chemistry (glutathione, metallothionein, the residue vocabulary of cysteine/methionine/sulfhydryl-driven binding) is the bridge to the peptide-remediation literature already collected in this folder (Luo 2024, Seregin 2023, Grill 1989, Marques 2025).

Limitations

• Narrative review without declared search strategy, inclusion criteria, or risk-of-bias assessment. Subsequent systematic reviews of chelation in specific clinical applications (e.g., Seely, Wu, Mills 2005 on EDTA chelation for cardiovascular disease — ref 109 in this paper) have characterised the underlying evidence base as small clinical trials with diverse outcomes and methodologies; this review does not attempt that synthesis.
• The Canadian Poison Control Centres questionnaire is reported as a narrative consensus with no quantitative parameters (n responding, response rate, regional distribution). The clinical preferences reported (DMSA-first for chronic lead, EDTA+BAL for acute lead, DMSA/DMPS for mercury) should be read as expert opinion in 2011 Canada, not a methodologically characterised survey.
• Several recommendations carry implicit endorsement framing (“Mineral status must be monitored during chelation therapy”) that is appropriate clinical practice but not derived from primary measurements within the manuscript. The review is best treated as a state-of-the-art summary at 2013, not as an evidence map.
• Some claims about animal studies are reported without sample-size or dose detail (the Sun-Microbiology cadmium-DMSA mouse comparison, the DMSA-versus-DMPS animal-brain methylmercury comparisons). Downstream uses should trace to the named primary citations (e.g., Andersen & Nielsen 1988, ref 83) before propagation.
• The TACT trial is described in terms of the primary composite endpoint but the source notes that urinary excretion of toxic elements was not assessed during the trial — i.e., the mechanism by which the EDTA arm achieved the cardiovascular benefit is not characterised in the paper. Subsequent commentary (ref 112) raised methodological concerns that the review does not adjudicate.

Wiki pages this source may touch

• lead
• cadmium
• arsenic-inorganic
• arsenic-total
• mercury-methyl
• mercury-total
• tin
• remediation-evidence

Verification notes

Existing-page check. DOI grep (10.1155/2013/219840), raw_handle grep (MFK_19-chelation-harnessing-and-enhancing-heavy-metal-), and cite-key glob (sears2013-*) over wiki/sources/ on 2026-06-08 returned no hits. This is a NEW source page with no prior version to merge-enhance.

Evidence tier. B (peer-reviewed narrative review). The paper reports no primary measurements, declares no systematic search strategy, and offers no risk-of-bias assessment. A-tier is reserved for primary peer-reviewed studies and authoritative agency monographs; this is neither. The author is a credentialed researcher at a major paediatric research institute and the review is the canonical reference for North American clinical chelation practice circa 2013, which supports B over C.

Metals frontmatter. The review explicitly discusses Pb, Cd, As (with both speciated iAs in the context of DMSA’s documented removal of “inorganic mercury” and “inorganic arsenic” exhaust mechanisms, and unspeciated As elsewhere), Hg (with both MeHg in the explicit methylmercury removal discussion and tHg elsewhere), Cr (mentioned only in the IARC carcinogen classification context, not as a chelator target), Sn (listed in the DMSA Table 1 elements-chelated column), Cu, Zn, Ag, Au, Se, Mg, and Ca (in the chelator/essential-mineral interaction discussion). From the HMTc 10-analyte priority list, Pb, Cd, iAs, tAs, MeHg, tHg, and Sn are recorded in metals:. Ni and Al are not discussed as primary review topics and are omitted. Cr-VI is not separately discussed (Cr appears only in carcinogen-classification context) and is omitted. Cu, Zn, Ag, Au, Se, Mg, Ca are out of the HMTc analyte vocabulary and are not added.

Ingredients, products, matrices frontmatter. All empty. The review measures nothing in any food, beverage, personal-care, or environmental matrix; it surveys clinical and dietary detoxification options without primary sampling. Garlic, broccoli, cilantro, bran, and modified citrus pectin + alginate are discussed as candidate detoxification adjuncts but no occurrence or exposure measurements appear; routing these to ingredient pages would misrepresent the source as occurrence-side evidence.

Jurisdictions. US and CA. The review is funded by Canadian Institutes of Health Research; the author is Canadian; the clinical-toxicologist survey is Canadian. The review cites US regulatory agencies extensively (FDA, EPA, NIH, CDC, IARC, ATSDR) and the principal clinical trials discussed are US (TACT, Cincinnati cohort, Adams) or US-cited (Lin et al. Taiwan, reported in NEJM and Kidney International). Recording both US and CA as in-scope jurisdictions.

Sample size. Null. This is a review with no sampling frame of its own.

Brand firewall (Part 12). The pharmaceutical-chelator Table 1 retains trade names (Chemet, Succicaptal, Endrate, Cuprimine, Depen, etc.) because the table catalogues drug-label vocabulary for the chelating agents — agents-of-treatment, parallel to instrument vendor names in a Methods section under the 2026-05-17 Exception 2 reading. The trade names attach to the chelators (the “instruments” doing the detoxification) and not to any contamination value of a sampled consumer product, which is what Part 12 targets. No other brand names appear in the review body. No firewall action required.

HMTc firewall (Part 2). The review contains no HMTc-threshold language and no claims of “consistent with the literature consensus that…” framing. It includes consumer-adjacent clinical practice recommendations (“Mineral status must be monitored during chelation therapy”; “Pharmaceutical chelating agents may also be considered, to assist with mobilization and excretion”) but these are scoped to the clinical-management context of a patient already in chelation therapy, not consumer-audience risk advisories about contaminated foods. The review is upstream of any HMTc rationale tagging.

Speciation discipline. The review consistently distinguishes inorganic arsenic from methylmercury in the toxicology framing (IARC classifications of “inorganic lead a probable carcinogen, and methylmercury a possible carcinogen”). It uses unspeciated “Hg” and “mercury” in the chelator-table elements-chelated column and in some clinical narrative. To avoid overspecification in the frontmatter, both iAs and tAs are recorded (the review discusses both inorganic As as a target of DMSA/DMPS chelation and As broadly), and both MeHg and tHg are recorded (the review explicitly discusses methylmercury removal from animal brains and unspeciated mercury elsewhere).

Reviewer note on scope fit. This paper is in scope per the 2026-06-02 commit 3f47f95 — scope: mitigation/remediation is in-scope, not a skip. The folder context (heavy_metals_peptides under Kimi_Agent_Black Market Peptide Metal Survey) indicates the curation intent is peptide-mediated metal binding and detoxification; this review’s emphasis on endogenous peptide chelators (glutathione, metallothionein) and the cysteine/sulfhydryl-coordination chemistry of DMSA/DMPS/BAL/penicillamine is the direct fit. It is not an occurrence study and contributes nothing to HMTc threshold-setting work, which is recorded accurately in the Implications section.

Date arithmetic. Received 15 February 2013, accepted 14 March 2013, published 2013 — consistent with year frontmatter. Article DOI 10.1155/2013/219840 resolves to The Scientific World Journal Volume 2013, Article ID 219840, 13 pages.

Open-access license. The paper is published by Hindawi Publishing Corporation under the Creative Commons Attribution License (the source text states “open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited”). The license version is not numbered in the source masthead; recorded as CC-BY-3.0 because Hindawi’s standard CC-BY policy in early 2013 was version 3.0. If a future audit determines the actual license was CC-BY-2.0 or unversioned, update accordingly.

Audit subagent (2026-06-08) verdict: PROMOTE. Five checks (numerical fidelity, slug vocabulary, speciation/methods, brand firewall, HMTc firewall) all returned ✅. One ⚠️ on the [[mitigation/remediation-evidence]] wikilink — the auditor noted this slug is outside the taxonomy snapshot’s four-category vocabulary (Ingredients/Products/Metals/Regulations) and asked Karen to confirm the target page exists. Verified independently in the same ingest session: wiki/mitigation/remediation-evidence.md exists in the wiki/mitigation/ subtree, which is the same legitimate routing destination the sibling peptide-folder pages (luo2024, etc.) target under the 2026-06-02 commit 3f47f95 — scope: mitigation/remediation is in-scope, not a skip. The taxonomy snapshot’s closed list is GPT-5.5’s drafting vocabulary, not the wiki’s exhaustive section index. No content corrections applied; the ⚠️ is a snapshot-scope artefact, not a defect in this page.

Page history

The five most recent substantive edits to this page. The full version history lives in git; when DOI minting comes online (see schema docs), each entry below will also link to a version-pinned DataCite DOI.